ArticleBMC public health2025
Spatiotemporal analysis of gastric cancer incidence in Iran from 2014 to 2018: a geospatial epidemiological study.
Article in BMC public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Gastric Cancer Incidence in Iran: Trends and Projections to 2030 based on Global Burden of Disease 2021 Estimates.Journal of gastrointestinal cancer · 2026Article
- Gastric cancer susceptibility mapping using GIS and machine learning in East Azerbaijan province, Iran.International journal of health geographics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGastric cancer (GC) is a well-known tumor with global implications. Previous studies in Iran have provided valuable insights into national incidence trends, but there is still a paucity of precise spatiotemporal analysis based on population-level cancer registry data. This gap in scientific knowledge needs correction through the use of modern geospatial approaches, which have the ability to provide localized preventative strategies. As a result, the primary goal of this research is to thoroughly examine the regional and temporal dynamics underpinning GC incidence in Iran.
methodsAge-standardized GC incidence rates were computed utilizing Iranian population-based cancer registry data from 2014 to 2018 across provinces and demographic strata. Global Moran's I assessed spatial autocorrelation and local indicators of spatial association cluster analysis delineated concentrated high and low-incidence clusters. Using space-time cube representations, emerging hot spot analysis highlighted spatiotemporal dynamics.
resultsThe analysis revealed significant inter-provincial inequalities, with Ardabil had the greatest incidence rate (34.2 per 100,000), whereas Hormozgan had the lowest (7.1 per 100,000). Males were shown to be more vulnerable across the board. While national incidence rates remained relatively stable from 2014 to 2018, the analyses revealed substantial provincial variation, with some regions showing intensifying high-incidence clusters (e.g., Gilan) and others displaying declining trends (e.g., Zanjan). Emerging Hot Spot Analysis revealed persistent pattern of high-incidence clustering in Ardabil, whereas Zanjan exhibited a diminishing hot spot trend, reflecting declining spatial significance over time.
conclusionThis geospatial analysis provides crucial insights into Iran's significant yet geographically variable GC burden. These findings underscore the importance of spatially-informed cancer surveillance and support further investigation into the underlying drivers of geographic variation in GC incidence. While not intended to guide direct interventions, the patterns observed may help shape future epidemiologic studies or hypothesis-driven screening strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.